Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham
Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s shares closed ...
American Association of Individual Investors2d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 11.26%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 11.26%, which has investors questioning if this is right time ...
bovnews2d
Lexicon Pharmaceuticals Inc (LXRX) Posted -4109.41% Profit Margin Last Year—Can It Hold Up?
Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $0.96 which represents a decrease of $-0.03 or -3.03% from the prior close of $0.99. The stock opened at $0.99 and touched a ...